IL5RA and acute myeloid leukemia: We next used the VEGFA inhibitor bevacizumab30, with no additional VEGF (as the AML cells express it already), and the IL5RA inhibitor benralizumab31 with or without exogenous IL-5, to test whether the inhibitors would abrogate growth stimulation.